Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > 4 Platform Drugmakers to Watch

September 26th, 2007

4 Platform Drugmakers to Watch

Abstract:
Abraxis BioScience (Nasdaq: ABBI) is developing drugs based on its nab (nanoparticle-albumin bound) technology. Essentially, the company takes chemotherapy drugs and surrounds them with albumin protein. Since albumin is used by tumor cells as a way to bring in nutrients, the tumor cells take up the albumin-bound drug more readily than they would a similar drug without albumin. The shell also increases the solubility of the drug, making it easier to deliver it to wherever it's needed in the body.

Abraxane, the company's one marketed drug based on the nab technology, has been competing well against the other taxanes on the market -- Bristol-Myers Squibb's (NYSE: BMY) Taxol and Sanofi-Aventis' (NYSE: SNY) Taxotere -- since it was approved to treat metastatic breast cancer in 2005. Abraxis is running additional clinical trials to get its label expanded to include other types of tumors.

The company is also developing four other chemotherapy drugs based on the nab technology. Two clinical trials for nab-docetaxel have already begun, and clinical studies for nab-rapamycin are expected to begin later this year. The other two molecules are still in pre-clinical trials but could be in the clinic as early as 2008.

Source:
fool.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events August 3rd, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017

Nanomedicine

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

JPK reports on how the University of Glasgow is using their NanoWizardŽ AFM and CellHesion module to study how cells interact with their surroundings August 2nd, 2017

Announcements

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Scientists from the University of Manchester and Diamond Light Source work with Deben to develop and test a new compression stage to study irradiated graphite at elevated temperatures August 15th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project